Moffitt Cancer Center

Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized ...
read more ↘

 

Videos
05:32

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Cell-Free utDNA to Detect MRD Prior to Repeat-Transurethral Resection of Bladder Tumor in NMIBC

FEATURING Kyle Rose
  • 29 views
  • February 22, 2023
05:36

Moffitt Cancer Center

Expert Commentary: Hemicolectomy vs. Appendectomy for Patients With Appendiceal Neuroendocrine Tumours 1-2 cm in Size

FEATURING Jonathan Strosberg
  • 56 views
  • February 14, 2023
  • 1
29:07

Moffitt Cancer Center

Updated Biomarker Prevalence and Testing Guidelines in Advanced NSCLC: Newly Actionable Biomarker KRAS G12C, EGFR exon 20, and HER2

FEATURING Bruna Pellini
  • 46 views
  • February 14, 2023
  • 1
07:46

ASCO GI 2023 Conference Coverage

FGFR2-Amplified Gastroesophageal Adenocarcinoma Is a Distinct Genomic Class: Lessons Learned From a Liquid Biopsy Platform

FEATURING Bushra Shariff
  • 29 views
  • February 7, 2023
  • 1
23:58

ASCO GI 2023 Conference Coverage

ASCO GI 2023 Key Studies

FEATURING Richard Kim, Rutika Mehta
  • 1,232 views
  • February 3, 2023
  • 10
07:20

ASCO GI 2023 Conference Coverage

ASCO GI 2023 ctDNA Informs Clinical Practice in Patients With Recurrent/Metastatic Gastroesophageal Cancers

FEATURING Rutika Mehta
  • 243 views
  • January 31, 2023
  • 2
44:23

MedNews Week

The Future of MDS Treatment

FEATURING Rami Komrokji
  • 252 views
  • January 25, 2023
  • 4
33:21

Moffitt Cancer Center

MRD in CLL/SLL: Is It Ready for Prime Time?

FEATURING Jose Sandoval-Sus
  • 217 views
  • January 25, 2023
  • 5
04:53

CancerGRACE

Neoadjuvant Therapy for Advanced Melanoma: Does It Give a Better Immune Response?

FEATURING Vernon Sondak
  • 236 views
  • January 19, 2023
  • 2
03:04

CancerGRACE

Personalized Response-Driven Surgery and Adjuvant Therapy After Neoadjuvant Ipi & Nivo in Resectable Stage III Melanoma: The PRADO Trial

FEATURING Vernon Sondak
  • 61 views
  • January 19, 2023
06:43

CancerGRACE

Pros and Cons of Neoadjuvant Therapy for Melanoma

FEATURING Vernon Sondak
  • 53 views
  • January 19, 2023
05:16

CancerGRACE

Patient Selection for 1L Therapy in Stage 4 Melanoma

FEATURING Vernon Sondak
  • 79 views
  • January 19, 2023
05:22

CancerGRACE

Treatment for Metastatic Melanoma

FEATURING Vernon Sondak
  • 172 views
  • January 19, 2023
03:39

CancerGRACE

Incidence Trends in Melanoma

FEATURING Vernon Sondak
  • 144 views
  • January 19, 2023
11:30

ASH 2022 Conference Coverage

ASH 2022 Post-Allogeneic Stem Cell Transplant Outcomes in Patients Treated With HMA + Venetoclax Compared to CPX-351

FEATURING Akriti Jain
  • 273 views
  • January 11, 2023
  • 1
06:06

ASH 2022 Conference Coverage

ASH 2022 Synergistic Activity of Luspatercept and Erythroid Stimulating Agents Combination for Treatment of Anemia in LR-MDS

FEATURING Rami Komrokji
  • 48 views
  • December 22, 2022
06:55

ASH 2022 Conference Coverage

ASH 2022 Luspatercept for Treatment of LR-MDS: Real World Data Replicates MEDALIST Study Results and Confirms Activity Among HMAs and Lenalidomide Treated Pts

FEATURING Rami Komrokji
  • 73 views
  • December 22, 2022
07:02

ASH 2022 Conference Coverage

ASH 2022 Phase 1 Results of the First-in-Class CXCR1/2 Inhibitor SX-682 in Pts With Hypomethylating Agent Failure MDS

FEATURING David Sallman
  • 30 views
  • December 22, 2022
26:45

Moffitt Cancer Center

Advancing Neoadjuvant Therapy of Melanoma: SWOG Trials S1512 & S1801

FEATURING Vernon Sondak
  • 69 views
  • December 21, 2022
07:30

ASH 2022 Conference Coverage

ASH 2022 Efficacy & Safety of Ruxolitinib for Treatment of Symptomatic CMML: Results of a Multicenter Phase II Clinical Trial

FEATURING Eric Padron
  • 33 views
  • December 19, 2022
  • 1
08:11

ASH 2022 Conference Coverage

ASH 2022: Validation of 2022 WHO & ICC Classifications in MDS - An Analysis on Behalf of the icMDS

FEATURING Somedeb Ball
  • 68 views
  • December 19, 2022
  • 3
05:55

ASH 2022 Conference Coverage

ASH 2022 Phase 3 ZUMA-7 Trial Updates: Association of Metabolic Tumor Volume and Clinical Outcomes in 2L R/R LBCL Following Axicabtagene Ciloleucel vs. SoC Therapy

FEATURING Frederick L. Locke
  • 57 views
  • December 16, 2022
09:39

Moffitt Cancer Center

NMIBC Unresponsive to BCG: Phase 2, Single Arm Study of CG0070 Combined with Pembro

FEATURING Roger Li
  • 28 views
  • November 25, 2022
15:29

Moffitt Cancer Center

Recognizing Signs and Symptoms of Gastric Cancer Progression: How to Look at It, How to Have Conversations With Patients, Conversations With Peers, When to Switch to 2L Treatment

FEATURING Rutika Mehta
  • 164 views
  • July 28, 2022
  • 2
01:23

Moffitt Cancer Center

Lecture Summary - 2L Therapies for Chronic and Persistent ITP

FEATURING Vania Phuoc
  • 8 views
  • July 11, 2022
18:26

Moffitt Cancer Center

2L Therapies for Chronic and Persistent ITP

FEATURING Vania Phuoc
  • 87 views
  • July 11, 2022
  • 1
07:55

Moffitt Cancer Center

Symptom Assessments in Myelofibrosis and How to Measure Spleen

FEATURING Andrew Kuykendall
  • 50 views
  • May 27, 2022
46:32

Moffitt Cancer Center

Genetic Risk Stratification for Prostate Cancer: Genomics, Ancestry, and Disparities

FEATURING Tyler Seibert
  • 49 views
  • April 13, 2022
21:30

Moffitt Cancer Center

Use of Cemiplimab in Locally Advanced Basal Cell Carcinomas After Hedgehog Inhibitor Therapy

FEATURING Zeynep Eroglu
  • 99 views
  • March 1, 2022
11:46

Moffitt Cancer Center

ASCO 2021 Updates from the PACIFIC Trial: Five-Year Survival Outcomes with Durvalumab After CRT in Unresectable Stage III NSCLC

FEATURING Alberto Chiappori
  • 237 views
  • November 11, 2021
47:46

Moffitt Cancer Center

Patients With Brain Tumors: New Tools and Techniques for Improved Surgical Outcomes

FEATURING Michael Vogelbaum
  • 9 views
  • September 21, 2021
17:07

Emerging Treatments in Oncology Weekly

Episode 3: Radiation Therapy in Merkel Cell Carcinoma in a Multidisciplinary Setting

FEATURING Evan Wuthrick
  • 20 views
  • August 20, 2021
19:20

Emerging Treatments in Oncology Weekly

Episode 2: Surgical Treatment of Merkel Cell Carcinoma in a Multidisciplinary Setting

FEATURING Rogerio Neves
  • 190 views
  • August 10, 2021
  • 4
21:20

Moffitt Cancer Center

2021 ASCO Updates on Triplet Therapy for Patients With BRAF-Mutated Advanced Melanoma

FEATURING Zeynep Eroglu
  • 529 views
  • July 5, 2021
  • 1
24:16

Moffitt Cancer Center

2021 ASCO Updates on KTE-X19 CAR T-Cell for Adult R/R B-Cell ALL: ZUMA-3 Study Data

FEATURING Bijal Shah
  • 46 views
  • June 29, 2021
08:47

Moffitt Cancer Center

Improved Tolerability of Neratinib in Patients With HER2+ EBC: The CONTROL Trial

FEATURING Hatem Soliman
  • 345 views
  • June 16, 2021
  • 1
11:40

Moffitt Cancer Center

World Lung IMpower133 Update on Maintenance Therapy in ES-SCLC: OS and PD-L1 Subgroup Data for Atezo Mono

FEATURING Bruna Pellini
  • 138 views
  • May 20, 2021
14:36

Emerging Treatments in Oncology Weekly

Episode 2: Principles of Neoadjuvant Therapy: Terminology, Pros and Cons, Patient & Treatment Selection, Preoperative & Total Treatment Duration, Response Assessment

FEATURING Vernon Sondak
  • 12 views
  • May 19, 2021
08:34

Emerging Treatments in Oncology Weekly

Episode 3: Neoadjuvant Therapy for Melanoma: Targeting BRAF V600Em Disease With BRAFi, CRR for BRAF+MEK Inhibitors, CPI Therapy, Imaging & pCR

FEATURING Vernon Sondak
  • 12 views
  • May 19, 2021
22:41

Moffitt Cancer Center

2021 Update on Pancoast Tumors: Signs & Symptoms, Treatment Options, Surgical Treatment Approaches & Outcomes

FEATURING Nam Tran
  • 40 views
  • April 13, 2021
  • 1
39:08

Moffitt Cancer Center

2021 Update on Pancoast Tumors: Presentation, Evaluation, Staging, Available Treatments & Limitations, Surgery Approach at Moffitt, Adverse Prognostic Factors

FEATURING Lary A Robinson
  • 46 views
  • April 13, 2021
  • 1
38:23

Moffitt Cancer Center

CD19-Directed CAR-T Cell Therapy Neurotoxicities: Can Tocilizumab Resolve CRS Cases/Neurotoxicity? What Are the Factors Associated With CRS & ICANS? Severe ICANS Histopathology and Correlates

FEATURING Bianca Santomasso
  • 13 views
  • March 11, 2021
10:54

Moffitt Cancer Center

Immune CPIs-Associated Neurotoxicity: Review of Neurologic irAEs, Encephalitis, Role of Pre-Existing Autoantibodies, Management Principles

FEATURING Bianca Santomasso
  • 148 views
  • March 11, 2021
  • 2
08:42

Moffitt Cancer Center

Cardio-Oncology Program at Moffitt Cancer Center: What Is Cardio-Oncology Program & Its Benefits?

FEATURING Guilherme Oliveira
  • 5 views
  • March 1, 2021
06:59

Moffitt Cancer Center

Moffitt Update on Cardio-Oncology: What Are the Cardiotoxic Effects of Cancer Treatments? What Are the Risk Factors?

FEATURING Roohi Ismail-Khan
  • 13 views
  • March 1, 2021
09:39

Moffitt Cancer Center

Cardiomyopathy & Heart Failure in Oncology Patients: How Can Radiation Therapy Amplify Cardiotoxicity? Is Trastuzumab Associated With Significant HF?

FEATURING Roohi Ismail-Khan
  • 8 views
  • March 1, 2021
05:31

Moffitt Cancer Center

Coronary Artery Disease, MI, PAD & Hypertension in Oncology Patients: What Is Cardiotoxicity Role of RT & TKIs?

FEATURING Roohi Ismail-Khan
  • 8 views
  • March 1, 2021
22:34

Moffitt Cancer Center

Monitoring, Prevention & Management of CVD in Cancer Patients: Which Patients Are at Increased Risk for Cardiac Dysfunction? Can Biomarkers and Strain Imaging Help With the Early Diagnosis? What Are the Management Recommendations?

FEATURING Mohammed Alomar
  • 79 views
  • March 1, 2021
  • 1
23:16

Moffitt Cancer Center

Hypotension in the Oncology Clinic Patients: Diagnosis, Management & Clinical Pearls

FEATURING Mark Honor
  • 3 views
  • February 26, 2021
05:43

Moffitt Cancer Center

79 y/o Male Treated for MDS, RBC Transfusion Dependent, With Anemia, DM, CKD, and Moderate Peripheral Neuropathy: How Would You Manage His Transfusions, and Medication Adjustments?

FEATURING Mark Honor
  • 146 views
  • February 26, 2021
06:08

Moffitt Cancer Center

61 y/o Male on Oral Chemo With Poor Intake, Longstanding History of HCTZ, and DM, BP 88/59: How to Approach Treatment?

FEATURING Mark Honor
  • 3 views
  • February 26, 2021
07:21

Moffitt Cancer Center

62 y/o Male With Tongue SCC, Hypothyroidism, OA, and Autonomic Neuropathy Causing Hypotension: How to Diagnose & Treat?

FEATURING Mark Honor
  • 4 views
  • February 26, 2021
14:09

Moffitt Cancer Center

Overview of Benign Prostatic Hyperplasia & LUTS: How to Identify & Quantify LUTS from BPH in Your Male Patients? What Are the AUA Guidelines for the Management of LUTS from BPH?

FEATURING Nainesh Parikh
  • 19 views
  • February 26, 2021
37:43

Moffitt Cancer Center

Moffitt Experience on Prostatic Artery Embolization & Cancer Patients QOL: What Is PAE, and What to Expect After the Procedure? What Questions to Ask Your Patients?

FEATURING Nainesh Parikh
  • 56 views
  • February 26, 2021
22:09

Moffitt Cancer Center

Moffitt Updates on AL Amyloidosis: Primary Systemic Disease Basics, Diagnostic Criteria/Workup, Organ Involvement, Hematologic/Organ Response

FEATURING Brandon Blue
  • 102 views
  • February 2, 2021
  • 1
31:49

Moffitt Cancer Center

AL Amyloidosis at Moffitt: How Does SCT Affect OS? Is Bortezomib/Ixazomib the Best Choice for Recurrent Disease vs. Mel/Dex? Is Doxycycline Beneficial After ASCT? Can We Achieve CHR With Dara+CyBorD in Newly Diagnosed Patients?

FEATURING Brandon Blue
  • 115 views
  • February 2, 2021
  • 1
19:57

Moffitt Cancer Center

Is Anti-CD38 Isatuximab-irfc Effective for R/R Multiple Myeloma?

FEATURING Kenneth Shain
  • 414 views
  • January 8, 2021
  • 1
21:59

Association of Community Cancer Centers (ACCC)

New Treatment Paradigms in Advanced CSCC

FEATURING Nikhil Khushalani
  • 199 views
  • December 29, 2020
  • 1
23:11

Association of Community Cancer Centers (ACCC)

Moffitt Cancer Center Updates on Advanced cSCC: How Do HLE & HLP Mimic the Disease? Are Multiple Biopsies Necessary and What Systemic Therapies to Use?

FEATURING Lucia Seminario-Vidal
  • 93 views
  • December 29, 2020
  • 1
14:39

Association of Community Cancer Centers (ACCC)

Moffit Cancer Center Highlights on XRT in Advanced cSCC: Early Stage, Brachytherapy, Side Effects, Indications for Post-Op XRT, Concurrent Chemo, Locally Advanced Disease

FEATURING Evan Wuthrick
  • 13 views
  • December 29, 2020
12:26

Moffitt Cancer Center

Moffitt Cancer Center Update on Metastatic Pancreatic Cancer: Does Nal-IRI+5FU/LV After Previous Gem-Based Chemo Improve OS?

FEATURING Dae Kim
  • 181 views
  • December 28, 2020
19:02

Moffitt Cancer Center

Moffitt Cancer Center Update on Advanced HCC: Is 1L Sorafenib Beneficial vs. Atezo + Bev? Can TKIs Be Used as 2L/3L Therapy?

FEATURING Richard Kim
  • 170 views
  • December 28, 2020
  • 1
16:30

Moffitt Cancer Center

Moffitt Cancer Center Update on mCRC: How Does FOLFOXIRI/Bev Combo Affect PFS2? Can We Use TAS-102 in Combo With Bev? Is Sidedness a Proxy for Biology and Is It Prognostic in All Stages?

FEATURING Thor Halfdanarson
  • 328 views
  • December 28, 2020
  • 4
19:36

Moffitt Cancer Center

Moffitt Cancer Center Update on Advanced Gastric Cancer: What Is the Role of HER2/VEGF Inhibition in Locally Advanced Disease? Is IO Recommended for PD-L1+ Metastatic Patients?

FEATURING Rutika Mehta
  • 39 views
  • December 28, 2020
14:57

Moffitt Cancer Center

Moffitt Cancer Center’s 2020 Update on MPNs: Overview, Epidemiology, Mutations, Prognostic Markers, Risk Factors

FEATURING Andrew Kuykendall
  • 257 views
  • December 15, 2020
  • 1
32:32

Moffitt Cancer Center

Moffitt Cancer Center’s 2020 Update on MPNs: Is Ruxolitinib Beneficial? Will the Disease Develop With Inflammation? How Do IL-1Beta & TNF-Alpha Work?

FEATURING Andrew Kuykendall
  • 474 views
  • December 15, 2020
  • 4
36:16

Moffitt Cancer Center

Hormones in Ovarian Cancer: Is There an Evidence Linking Menopausal HT With Ovarian/BC Incidence, Treatment and QoL? What Role Does the HRT Play?

FEATURING Gina Woodward, Lindsay Tedder
  • 17 views
  • December 9, 2020
11:15

Moffitt Cancer Center

COVID-19: What is the Death Risk Among Patients With Asthma & COPD? Which Factors Increase Community Spread & Which Conditions Increase the Risk for Hospitalization?

FEATURING Amit K Tandon
  • 1,224 views
  • November 26, 2020
  • 7
10:01

Moffitt Cancer Center

COVID-19 in Lung Cancer Patients: Does Chemotherapy Increase the Severity of COVID-19? Is (Neo)Adjuvant Chemotherapy Still Recommended? What if a Patient Is Coronavirus Positive?

FEATURING Michael Shafique
  • 116 views
  • November 26, 2020
15:04

Moffitt Cancer Center

COVID-19 & Surgery at Moffitt Cancer Center: What Is the Inflammatory Response to Surgery and Anesthesia? What Acute Systemic Changes Occur With COVID-19 Infection?

FEATURING Lary A Robinson
  • 192 views
  • November 26, 2020
  • 1
07:04

Moffitt Cancer Center

When Can a Diagnostic Test Detect SAR-CoV-2? In Which Order Do COVID-19 Symptoms Usually Show Up? How Does the Virus Progress Through the Body Over Time?

FEATURING John Greene
  • 1,058 views
  • November 26, 2020
  • 1
19:58

Moffitt Cancer Center

COVID-19: Are Family & Upcoming Large Holiday Gatherings Safe? Can Close Contact and Intense Physical Activity Contribute to Spread?

FEATURING John Greene
  • 3,492 views
  • November 26, 2020
  • 25
09:21

Moffitt Cancer Center

Melanoma Therapy During COVID-19: How to Deal With Coronavirus Positive Patients Undergoing RT? What Happens To Patients in Clinical Trial if They Are Infected?

FEATURING Evan Wuthrick, Allison Richards, Vernon Sondak
  • 111 views
  • November 16, 2020
12:50

Moffitt Cancer Center

Melanoma Drug Therapy During COVID-19: When to Wait or Go Forward With the Adjuvant Treatment? Does IO Help Fight Coronavirus? Are Pts on Steroids at Higher Risk for the Virus? How Long After a Treatment a Patient Should Be Monitored?

FEATURING Zeynep Eroglu, Vernon Sondak
  • 375 views
  • November 16, 2020
  • 1
14:59

Moffitt Cancer Center

Treatment Options in Ovarian Cancer: What Role Do Maintenance PARPi Play? How Does HIPEC OS Data Compare to IV/IP + Bev?

FEATURING Robert Wenham
  • 96 views
  • November 13, 2020
05:19

Moffitt Cancer Center

2020 Updates on Genetic Testing for GYN Malignancies: Germline vs. Somatic Mutations - What Is the Risk for Ovarian Cancer?

FEATURING Jeannie Chern
  • 194 views
  • November 13, 2020
39:12

Moffitt Cancer Center

60 y/o GO With Irregular and Heavy Vaginal Bleeding: What Surgical Procedure Should We Use? Chemo vs. Chemoradiotherapy - Which Is More Beneficial for Endometrial Cancer?

FEATURING Ardeshir Hakam, Jeannie Chern, Mitchel Hoffman, Robert Wenham, Michael Montejo
  • 122 views
  • November 13, 2020
  • 1
11:41

Moffitt Cancer Center

Surgical Options in Endometrial Cancer: How We Have Advanced to Minimally Invasive Surgery as the Standard Approach

FEATURING Mitchel Hoffman
  • 15 views
  • November 13, 2020
14:20

Moffitt Cancer Center

2020 ASCO Update on R/R AML: Cytarabine/Daunorubicin vs. 7+3 Chemo - What Option Provides Better OS and Long-Term Remission in Older Patients?

FEATURING Jeffrey Lancet
  • 56 views
  • September 29, 2020